Syndecan-1, a cell surface proteoglycan, negatively regulates initial leukocyte recruitment to the brain across the choroid plexus in murine experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 191, Issue 9, 2013, Pages 4551-4561

  Zhang, Xueli ^a   Wu, Chuan ^a,b   Song, Jian ^a   Götte, Martin ^a   Sorokin, Lydia ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; SYNDECAN 1; CCL20 PROTEIN, MOUSE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL SURVIVAL; CEREBROSPINAL FLUID; CHOROID PLEXUS; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LEUKOCYTE ACTIVATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OLIGODENDROGLIA; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TH1 CELL; TH17 CELL; UPREGULATION; ANIMAL; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETICS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOKINE CCL20; CHOROID PLEXUS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; PLASMA CELLS; SIGNAL TRANSDUCTION; SYNDECAN-1; TH17 CELLS; UP-REGULATION;

EID: 84886063101     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300931     Document Type: Article

References (61)

1. Parish, C. R. 2006. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 6: 633-643.
2. Proudfoot, A. E. 2006. The biological relevance of chemokine-proteoglycan interactions. Biochem. Soc. Trans. 34: 422-426.
3. Forsten-Williams, K., C. L. Chu, M. Fannon, J. A. Buczek-Thomas, and M. A. Nugent. 2008. Control of growth factor networks by heparan sulfate proteoglycans. Ann. Biomed. Eng. 36: 2134-2148.
4. Yayon, A., M. Klagsbrun, J. D. Esko, P. Leder, and D. M. Ornitz. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841-848.
5. Rapraeger, A. C., A. Krufka, and B. B. Olwin. 1991. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252: 1705-1708.
6. 5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 206: 691-705.
7. Morgan, M. R., M. J. Humphries, and M. D. Bass. 2007. Synergistic control of cell adhesion by integrins and syndecans. Nat. Rev. Mol. Cell Biol. 8: 957-969.
8. Hassan, H., B. Greve, M. S. Pavao, L. Kiesel, S. A. Ibrahim, and M. Götte. 2013. Syndecan-1 modulates b-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J. 280: 2216-2227.
9. Bernfield, M., M. Götte, P. W. Park, O. Reizes, M. L. Fitzgerald, J. Lincecum, and M. Zako. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68: 729-777.
10. Rapraeger, A. C. 2000. Syndecan-regulated receptor signaling. J. Cell Biol. 149: 995-998.
11. Park, P. W., O. Reizes, and M. Bernfield. 2000. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J. Biol. Chem. 275: 29923-29926.
12. Subramanian, S. V., M. L. Fitzgerald, and M. Bernfield. 1997. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J. Biol. Chem. 272: 14713-14720.
13. Teng, Y. H.-F., R. S. Aquino, and P. W. Park. 2012. Molecular functions of syndecan-1 in disease. Matrix Biol. 31: 3-16.
14. Kharabi Masouleh, B., G. B. Ten Dam, M. K. Wild, R. Seelige, J. van der Vlag, A. L. Rops, F. G. Echtermeyer, D. Vestweber, T. H. van Kuppevelt, L. Kiesel, and M. Götte. 2009. Role of the heparan sulfate proteoglycan syndecan-1 (CD138) in delayed-type hypersensitivity. J. Immunol. 182: 4985-4993.
15. Floer, M., M. Götte, M. K. Wild, J. Heidemann, E. S. Gassar, W. Domschke, L. Kiesel, A. Luegering, and T. Kucharzik. 2010. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am. J. Pathol. 176: 146-157.
16. Hayashida, K., W. C. Parks, and P. W. Park. 2009. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood 114: 3033-3043.
17. Sanderson, R. D., P. Lalor, and M. Bernfield. 1989. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1: 27-35.
18. McDermott, S. P., E. A. Ranheim, V. S. Leatherberry, S. S. Khwaja, K. S. Klos, and C. M. Alexander. 2007. Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development. Oncogene 26: 1407-1416.
19. Elenius, K., S. Vainio, M. Laato, M. Salmivirta, I. Thesleff, and M. Jalkanen. 1991. Induced expression of syndecan in healing wounds. J. Cell Biol. 114: 585-595.
20. Reboldi, A., C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli, S. Lira, A. Uccelli, A. Lanzavecchia, B. Engelhardt, and F. Sallusto. 2009. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10: 514-523.
21. Alexander, C. M., F. Reichsman, M. T. Hinkes, J. Lincecum, K. A. Becker, S. Cumberledge, and M. Bernfield. 2000. Syndecan-1 is required for Wnt1-induced mammary tumorigenesis in mice. Nat. Genet. 25: 329-332.
22. Kallies, A., J. Hasbold, D. M. Tarlinton, W. Dietrich, L. M. Corcoran, P. D. Hodgkin, and S. L. Nutt. 2004. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J. Exp. Med. 200: 967-977.
23. Agrawal, S., P. Anderson, M. Durbeej, N. van Rooijen, F. Ivars, G. Opdenakker, and L. M. Sorokin. 2006. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203: 1007-1019.
24. 2-integrin negative polymorphonuclear granulocytes on defined extracellular matrix molecules. Relevance for leukocyte extravasation. J. Biol. Chem. 276: 18878-18887.
25. Manitz, M. P., B. Horst, S. Seeliger, A. Strey, B. V. Skryabin, M. Gunzer, W. Frings, F. Schönlau, J. Roth, C. Sorg, and W. Nacken. 2003. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23: 1034-1043.
26. Hallmann, R., D. N. Mayer, E. L. Berg, R. Broermann, and E. C. Butcher. 1995. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev. Dyn. 202: 325-332.
27. Wu, C., F. Ivars, P. Anderson, R. Hallmann, D. Vestweber, P. Nilsson, H. Robenek, K. Tryggvason, J. Song, E. Korpos, et al. 2009. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat. Med. 15: 519-527.
28. Sixt, M., B. Engelhardt, F. Pausch, R. Hallmann, O. Wendler, and L. M. Sorokin. 2001. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J. Cell Biol. 153: 933-946.
29. Matsushita, T., K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
30. Krishnamoorthy, G., H. Lassmann, H. Wekerle, and A. Holz. 2006. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116: 2385-2392.
31. Liu, L., and K. Duff. 2008. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J. Vis. Exp. 21: 960.
32. (-δ δ C(T)) Method. Methods 25: 402-408.
33. Wu, C., U. Rauch, E. Korpos, J. Song, K. Loser, P. R. Crocker, and L. M. Sorokin. 2009. Sialoadhesin-positive macrophages bind regulatory T cells, negatively controlling their expansion and autoimmune disease progression. J. Immunol. 182: 6508-6516.
34. Ransohoff, R. M., P. Kivisäkk, and G. Kidd. 2003. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3: 569-581.
35. Arima, Y., M. Harada, D. Kamimura, J. H. Park, F. Kawano, F. E. Yull, T. Kawamoto, Y. Iwakura, U. A. Betz, G. Márquez, et al. 2012. Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 148: 447-457.
36. Meares, G. P., X. Ma, H. Qin, and E. N. Benveniste. 2012. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 60: 771-781.
37. Okuda, Y., S. Sakoda, C. C. Bernard, H. Fujimura, Y. Saeki, T. Kishimoto, and T. Yanagihara. 1998. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10: 703-708.
38. Xu, J., P. W. Park, F. Kheradmand, and D. B. Corry. 2005. Endogenous attenuation of allergic lung inflammation by syndecan-1. J. Immunol. 174: 5758-5765.
39. Jiang, D., J. Liang, G. S. Campanella, R. Guo, S. Yu, T. Xie, N. Liu, Y. Jung, R. Homer, E. B. Meltzer, et al 2010. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J. Clin. Invest. 120: 2049-2057.
40. Pöllinger, B., G. Krishnamoorthy, K. Berer, H. Lassmann, M. R. Bösl, R. Dunn, H. S. Domingues, A. Holz, F. C. Kurschus, and H. Wekerle. 2009. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 206: 1303-1316.
41. Fairfax, K. A., L. M. Corcoran, C. Pridans, N. D. Huntington, A. Kallies, S. L. Nutt, and D. M. Tarlinton. 2007. Different kinetics of blimp-1 induction in B cell subsets revealed by reporter gene. J. Immunol. 178: 4104-4111.
42. Hasan, L., L. Mazzucchelli, M. Liebi, M. Lis, R. E. Hunger, A. Tester, C. M. Overall, and M. Wolf. 2006. Function of liver activation-regulated chemokine/CC chemokine ligand 20 is differently affected by cathepsin B and cathepsin D processing. J. Immunol. 176: 6512-6522.
43. + T-cell recruitment to target tissues. Eur. J. Immunol. 39: 1671-1681.
44. Elhofy, A., R. W. Depaolo, S. A. Lira, N. W. Lukacs, and W. J. Karpus. 2009. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. J. Neuroimmunol. 213: 91-99.
45. Serada, S., M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, H. Yoshida, T. Nishikawa, F. Terabe, T. Ohkawara, et al. 2008. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105: 9041-9046.
46. Hayashida, K., Y. Chen, A. H. Bartlett, and P. W. Park. 2008. Syndecan-1 is an in vivo suppressor of Gram-positive toxic shock. J. Biol. Chem. 283: 19895-19903.
47. Baston-Büst, D. M., M. Götte, W. Janni, J. S. Krüssel, and A. P. Hess. 2010. Syndecan-1 knock-down in decidualized human endometrial stromal cells leads to significant changes in cytokine and angiogenic factor expression patterns. Reprod. Biol. Endocrinol. 8: 133.
48. Schneider, C., N. Kassens, B. Greve, H. Hassan, A. N. Schuring, A. StarzinskiPowitz, L. Kiesel, D. G. Seidler, and M. Gotte. 2013. Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion. Fertil. Steril. 99: 871-881 e871.
49. Szatmári, T., F. Mundt, G. Heidari-Hamedani, F. Zong, E. Ferolla, A. Alexeyenko, A. Hjerpe, and K. Dobra. 2012. Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells. PLoS One 7: e48091.
50. Sebestyén, A., M. Gallai, T. Knittel, T. Ambrust, G. Ramadori, and I. Kovalszky. 2000. Cytokine regulation of syndecan expression in cells of liver origin. Cytokine 12: 1557-1560.
51. Birch, M. A., and T. M. Skerry. 1999. Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones. Bone 24: 571-578.
52. Sneed, T. B., D. J. Stanley, L. A. Young, and R. D. Sanderson. 1994. Interleukin6 regulates expression of the syndecan-1 proteoglycan on B lymphoid cells. Cell. Immunol. 153: 456-467.
53. Mummery, R. S., and C. C. Rider. 2000. Characterization of the heparin-binding properties of IL-6. J. Immunol. 165: 5671-5679.
54. Ramsden, L., and C. C. Rider. 1992. Selective and differential binding of interleukin (IL)-1a, IL-1b, IL-2 and IL-6 to glycosaminoglycans. Eur. J. Immunol. 22: 3027-3031.
55. Kishimoto, T. 2005. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23: 1-21.
56. Samoilova, E. B., J. L. Horton, B. Hilliard, T. S. Liu, and Y. Chen. 1998. IL6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161: 6480-6486.
57. Leech, M. D., T. A. Barr, D. G. Turner, S. Brown, R. A. O'Connor, D. Gray, R. J. Mellanby, and S. M. Anderton. 2013. Cutting edge: IL-6-dependent autoimmune disease - dendritic cells as a sufficient, but transient, source. J. Immunol. 190: 881-885.
58. Kainulainen, V., L. Nelimarkka, H. Järveläinen, M. Laato, M. Jalkanen, and K. Elenius. 1996. Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-a. J. Biol. Chem. 271: 18759-18766.
59. Morris-Downes, M. M., P. A. Smith, J. L. Rundle, S. J. Piddlesden, D. Baker, D. Pham-Dinh, N. Heijmans, and S. Amor. 2002. Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J. Neuroimmunol. 125: 114-124.
60. von Büdingen, H. C., S. L. Hauser, J. C. Ouallet, N. Tanuma, T. Menge, and C. P. Genain. 2004. Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur. J. Immunol. 34: 2072-2083.
61. Zhou, D., R. Srivastava, S. Nessler, V. Grummel, N. Sommer, W. Brück, H. P. Hartung, C. Stadelmann, and B. Hemmer. 2006. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103: 19057-19062.